证券代码：002173 证券简称：千足珍珠 千足珍珠集团股份有限公司投资者关系活动记录表 编号：2015-02 | --- | --- | --- | |------------------------------------|------------------------------|----------------------------------------------------------------------------| | | | | | | | | | 投资者关系活动类别 | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 | 现场投资者接待日活动 | | 参与单位名称及人员姓名 | | 北京立名投资管理有限公司赵悦，浙商证券研究所程艳华、曹 | | | | 梦悦、刘楠，深圳睿泉毅信投资管理有限公司吴雅春，上海通 | | | | 金投资有限公司陈坤，民生证券毕海委，中信建投证券陈萌， | | | | 中海基金管理有限公司焉娇、郑辰，鹏华基金金笑非，东海证 ...

证券代码：002173 证券简称：千足珍珠 千足珍珠集团股份有限公司投资者关系活动记录表 编号：2015-01 | --- | --- | --- | |------------------------------------------------------|------------------------------|----------------------------------------------------------------------------------| | | | | | 投资者关系活动类别 | □ 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 | 现场投资者接待日活动 | | 参与单位名称及人员姓名 | 无 | | | 时间 | 2015 年 5 月 18 日 | 上午 9 点 30 分至 11 点 30 分 | | 地点 | 公司五楼会议室 | | | 上市公司接待人员姓名 | | 董事长兼总裁陈海军、董秘兼副总裁马三光、财务总监洪全付、 ...

Group 1: Company Overview - The company operates in two main sectors: pearl processing and sales, and medical services [3] - The pearl industry faces significant challenges due to complex international and domestic environments, with a notable decline in pearl production and prices remaining low despite reduced supply [3] Group 2: Financial Performance - In the first half of 2016, the company reported revenue of 36.8964 million yuan, a decrease of 51.79% compared to the same period last year [3] - The net profit for the same period was -27.8095 million yuan, down 64.44% year-on-year [3] Group 3: Hospital Integration and Performance - The company has acquired three hospitals and is focused on integrating them, with the goal of building a distinctive and innovative healthcare industry cluster [4] - As of June 30, 2016, two of the hospitals have met half of their promised performance for the year, while one hospital is underperforming due to seasonal patient discharge issues [4] Group 4: Future Strategies - The company plans to unify management across the three hospitals and establish effective management processes [6] - Future acquisitions will focus on profitable hospitals, and the company does not plan to build new hospitals or partner with non-profit public hospitals due to high risks and costs [5]

证券代码：002173 证券简称：*ST 创疗 创新医疗管理股份有限公司投资者关系活动记录表 编号：2016-02 | --- | --- | --- | |--------------------------------------|----------------------------------|----------------------------------------------------------------------------------| | | | | | | | | | 投资者关系活动类别 | □ 特定对象调研 | □ 分析师会议 | | | 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | 每日经济新闻 | 记者 沈溦 | | 时间 | 2016 年 9 月 28 日上午 | 10 点 ~11 点 | | 地点 | 浙江省杭州市求是路 | 8 号公元大厦北楼 303A 室 | | 上市公司接待人员姓名 | 董事会秘书兼副总裁傅震刚 | | | 现场采访活动主 ...

编号：2016-03 √特定对象调研 □分析师会议 投资者关系 √媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 □其他 参与单位名 国投瑞银张佳荣、浦银安盛刘诗瑶、上投摩根方珏涵、交银施罗德楼慧源、富国 称及人员姓 基金姜恩铸、鹏华基金金笑非、陈璇淼、中邮基金容杰、泰信基金徐慕浩、中海 名 基金郑辰、民生通惠罗丹、中原证券张洋、太平洋证券耿广棋、程艳华、西部证 券王宗凯、趋时资产罗会礼、长安信托杨小馨、证券时报吕婧、李小平、滚石投 资王广军、王超、上海昶享资产徐幸福、东方创新毕海委、立名投资柯良友、致 君资产李涛、同犇投资周雅洁、涌悦资产成胜、彤源投资庄琰、源实资产江琦、 浙商证券杨云、曹梦悦、刘楠、中信证券曹阳、九富投资王新华、范瑞、中欧基金 姜祎、李欣 证券代码：002173 证券简称：*ST 创疗 创新医疗管理股份有限公司投资者关系活动记录表 | --- | --- | |------------|----------------------------------------------------------------------| | 时间 | 2016 年 10 月 ...

证券代码：002173 证券简称：*ST 创疗 创新医疗管理股份有限公司投资者关系活动记录表 编号：2016-04 | --- | --- | --- | |----------------------------------------|------------------------------|------------------------------------------------------------------------------| | | | | | | | | | 投资者关系活动类别 | □ 特定对象调研 | □ 分析师会议 | | | √ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | | | 参与单位名称及人员姓名 | 诸暨日报胡子昂、冯杭洁 | | | 时间 | 2016 年 12 月 2 日 | 上午 10:00 至 11:30 | | 地点 | 公司五楼会议室 | | | 上市公司接待人员姓名 | | 副总裁兼董事会秘书傅震刚、证券事务代表张玉兰 | | 现场调研活动主要内容介绍： | | ...

创新医疗管理股份有限公司 投资者关系活动记录 创新医疗管理股份有限公司 投资者关系活动记录表 | --- | --- | |--------------------|------------------------------------------------------------------------------------------------| | | | | | √ 公司现场接待 □ 电话接待 | | 投资者关系活动类别 | □ 其他场所接待 □ 公开说明会 | | | □ 定期报告说明会 □ 重要公告说明会 | | | □ 其他（请文字说明其他活动内容） | | | 浙江广电集团广播经济频道《走进上市公司》栏目组 | | 参与单位及人员姓名 | （5 人）：陈正忠、李耸、张舒、庄严、周凤娣 个人投资者（ 6 人）：徐文煊、何煦能、卞央维、蔡 | | | 家超、朱睿莹、贺韵琴 | | 时间 | 2018 年 9 月 20 日 | | 地点 | 杭州市西湖区求是路 8 号公元大厦北楼 303A | | | 副总经理兼董事会秘书 田金明 | | 上市公司接待人员 | 证券部 季仕才、郭立丹 | | ...

证券代码：002173 证券简称：创新医疗 公告编号：2022-066 创新医疗管理股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证 季度报告中财务信息的真实、准确、完整。 3、第三季度报告是否经过审计 创新医疗管理股份有限公司 2022 年第三季度报告 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比 上年同期增减 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | | | 增减 | | 营业收入（元） | 204,978,861.32 | 23.52% | 540,574,309.85 | 1.23% | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥335,595,448.53, a decrease of 8.82% compared to ¥368,050,497.79 in the same period last year[17]. - The net loss attributable to shareholders was ¥48,076,544.67, representing a 119.27% increase in losses compared to a net loss of ¥21,925,534.04 in the previous year[17]. - Basic and diluted earnings per share were both -¥0.11, reflecting a 120.00% increase in losses compared to -¥0.05 in the previous year[17]. - The company reported a total revenue of approximately CNY 860.19 million for the first half of 2022, with a net profit of CNY 130.35 million, reflecting a decrease of CNY 6.76 million compared to the previous period[59]. - The total comprehensive loss for the first half of 2022 was approximately ¥48.29 million, compared to a comprehensive income of ¥26.36 million in the first half of 2021, marking a significant decline[169]. - The total revenue for the first half of 2022 was reported at 453,609,000 CNY, reflecting a significant increase compared to the previous period[126]. - The company reported a net profit margin of 8% for the first half of 2022, indicating a stable profitability level[126]. Cash Flow and Assets - The net cash flow from operating activities was -¥85,618,564.22, a significant decline of 3,315.37% from a positive cash flow of ¥2,662,791.59 in the same period last year[17]. - The company reported a substantial increase in cash flow from investment activities, reaching ¥512,424,232.05, up 891.25% year-on-year, mainly due to the redemption of financial products[32]. - The company's cash and cash equivalents increased significantly to CNY 649,818,356.30, accounting for 27.17% of total assets, up from 9.45% the previous year[39]. - The total assets at the end of the reporting period were ¥2,391,736,905.46, down 6.43% from ¥2,556,184,699.61 at the end of the previous year[17]. - The company's accounts receivable increased to CNY 119,965,915.84, representing 5.02% of total assets, up from 3.49% the previous year[39]. - The total current liabilities decreased to CNY 239.66 million from CNY 307.83 million, a reduction of approximately 22.1%[158]. Operational Challenges - Total operating revenue for the reporting period was ¥335,595,448.53, down 8.82% compared to the previous year, primarily due to the ongoing impact of the pandemic and related control measures[32]. - The company faces significant risks and challenges, which are detailed in the section on risks and countermeasures in the report[4]. - The ongoing impact of the pandemic has resulted in structural changes in hospital operations, with the company implementing strategies to maintain effective epidemic prevention measures[62]. - The company reported a decrease in inventory to CNY 32,986,364.51, which accounted for 1.38% of total assets, down from 1.80% the previous year[39]. Strategic Initiatives - The company plans to enhance its core competitiveness through refined management and the introduction of specialized medical talents across its hospitals[29]. - The company is actively adapting to changes in healthcare policies to enhance service quality and meet the evolving demands of the healthcare sector[60]. - The company is focusing on retaining and attracting medical talent by improving incentive systems and enhancing employee training and satisfaction[64]. - The company plans to expand its market presence and invest in new product development to drive future growth[177]. Social Responsibility and Compliance - The company has conducted over 14 free medical consultation events, serving approximately 1,100 individuals in the first half of 2022, promoting health awareness and disease prevention[88]. - The company has supported over 30 community nucleic acid testing points, conducting sampling for more than 1.14 million individuals since May 2022, demonstrating commitment to public health during the pandemic[85]. - The company has established a medical waste management system, ensuring proper storage, handling, and disposal of medical waste, with regular training for staff on waste management protocols[76]. - The company has maintained transparency and compliance with legal regulations, ensuring timely and accurate information disclosure to protect shareholder and creditor rights[80]. Legal and Regulatory Matters - The company is currently involved in arbitration regarding the performance compensation dispute, and the outcome remains uncertain[93]. - The company reported a contingent liability of 130,420,805.20 RMB related to a financing lease dispute with Baoxin International[98]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[94]. - The company has not undergone any bankruptcy reorganization during the reporting period[105]. Shareholder and Equity Information - The total number of shares outstanding after the changes was 372,252,021, with 81.85% being unrestricted shares[131]. - The company repurchased and canceled a total of 1,246,735 shares at a total price of 1 CNY, with an additional 530,047 shares repurchased and canceled in February 2022[132]. - The company’s stockholders have not proposed any applications for lifting restrictions on shares, and related procedures have not been processed[139]. - The total number of ordinary shareholders at the end of the reporting period was 30,819[142].

Financial Performance - The company's operating revenue for 2021 was ¥711,515,518.12, a decrease of 1.76% compared to ¥724,243,049.01 in 2020[20] - The net profit attributable to shareholders was -¥105,225,864.63, an improvement of 66.54% from -¥314,501,943.35 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥91,724,759.57, showing a 65.66% increase compared to -¥267,074,741.63 in 2020[20] - The net cash flow from operating activities was ¥43,370,331.70, a decline of 67.06% from ¥131,665,941.48 in 2020[20] - The basic earnings per share improved to -¥0.23, up 66.67% from -¥0.69 in the previous year[20] - The diluted earnings per share for 2021 was -0.23 CNY, an improvement of 66.67% compared to -0.69 CNY in 2020[21] - The total assets at the end of 2021 were 2,556,184,699.61 CNY, a decrease of 4.53% from 2,677,542,017.40 CNY at the end of 2020[21] - The net assets attributable to shareholders decreased by 7.17% to 1,989,808,178.69 CNY at the end of 2021 from 2,143,437,756.92 CNY at the end of 2020[21] - The company reported a net cash flow from operating activities of -9,888,396.53 CNY in Q1 and 12,551,188.12 CNY in Q2, indicating fluctuations in cash flow[25] Strategic Transformation - The company has undergone a strategic transformation to focus on high-quality medical services, moving away from its previous pearl-related business[19] - The company completed a major asset restructuring in 2016, adding three subsidiaries in the medical service sector[19] - The company is focusing on expanding its core departments and enhancing service quality to improve patient care[33] - The company aims to enhance its management capabilities through refined management practices and improve operational efficiency[33] Hospital Performance - Jianhua Hospital's revenue was 399.88 million yuan, a year-on-year decline of 6.64%, while the net profit was -94.83 million yuan, with a year-on-year reduction in losses of 60.79%[38] - Kanghua Hospital reported revenue of 292.69 million yuan, a year-on-year increase of 3.87%, but the net profit decreased by 46.95% to 5.74 million yuan[39] - Futen Hospital's revenue reached 15.74 million yuan, a year-on-year increase of 11.30%, with a net profit of -13.58 million yuan, reducing losses by 14.39%[41] - Mingzhu Hospital generated revenue of 74.22 million yuan, a year-on-year increase of 16.93%, while the net profit was -7.82 million yuan, a year-on-year decrease of 3.08%[42] Government and Regulatory Compliance - The audit report for the annual report was issued with a qualified opinion by Lixin Certified Public Accountants[5] - The company has fulfilled its information disclosure obligations regarding fundraising management and has no violations in this area[94] - The company has not faced any significant discrepancies in governance compared to regulatory requirements[121] - The company has not reported any non-operating fund occupation by controlling shareholders or other related parties during the reporting period[183] Legal and Financial Matters - The company is actively involved in legal proceedings to recover funds and address disputes with financial institutions[89] - A court ruling mandated the return of 24,969,028.26 to the company from the bank, along with interest calculated at a rate of 0.3%[88] - The company reached a settlement agreement with Baoxin International regarding a financing lease contract dispute, which has been approved by the shareholders' meeting[200] - The total amount involved in the financing lease contract dispute with Baoxin International was approximately 778.99 million[200] Research and Development - The company is exploring potential acquisitions to bolster its technology capabilities, with a budget of 500 million RMB allocated for this purpose[134] - The company is currently in the R&D investment phase for Boling Technology and does not expect to generate business revenue in the short term[114] - The first generation prototype of the BCI technology for assisting stroke patients has been successfully developed, with further research and development ongoing[113] Employee and Governance - The company has established a transparent performance evaluation and incentive mechanism for directors and senior management, ensuring compliance with legal standards[119] - The company reported a total of 587 doctors, 996 nurses, and 329 medical technicians among its employees[155] - The company has a structured salary policy that links employee performance with economic benefits, aiming to motivate staff[156] - The company has implemented various corrective measures to enhance environmental awareness and management practices across its subsidiaries[169] Social Responsibility and Community Engagement - The company organized free medical consultations for over 3,000 individuals in impoverished rural areas in 2021, distributing free medications and masks[176] - The company participated in COVID-19 prevention efforts, mobilizing over 200 medical staff for various tasks, including 7 city-wide nucleic acid testing events and 3 vaccination campaigns[175] - The company has received multiple commendations from health authorities for its effective management and layout of vaccination sites during the pandemic[176] Future Outlook - The company plans to continue expanding its market presence through new projects and investments in healthcare facilities[80] - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% to 1.875 billion RMB[136] - The management emphasized a commitment to sustainability, with plans to reduce carbon emissions by 15% by 2025[134]